Arachidonoyl ethanolamide （AEA） was the first endogenous cannabinoid to be isolated and characterized as an agonist acting on the same receptors （CB1 and CB2） as tetrahydrocannabinols （THC）. Arachidonoyl cyclopropamide （ACPA） is a potent， stable， and selective agonist analog of AEA. ACPA has an Ki value of 2.2 nM at the isolated rat CB1 receptor， and is 325 times more potent at the CB1 receptor compared with the CB2 receptor. In whole animal experiments， ACPA induces hypothermia in mice with the same efficacy as AEA， in spite of its much higher affinity for the CB1 receptor. These data have been interpreted to indicate that ACPA may be a substrate for fatty acid amide hydrolase （FAAH）， and thus only transiently available in whole animal experiments.
产品描述
A potent， stable， and selective agonist analog of AEA with a Ki value of 2.2 nM at the isolated rat CB1 receptor； 325 times more potent at the CB1 receptor compared with the CB2 receptor； induces hypothermia in mice with the same efficacy as AEA， in spite of its much higher affinity for the CB1 receptor and thus is a possible substrate for FAAH
